Ovidio nella riscrittura di Albrecht von Halberstadt

The reworking of Ovid's Metamorphoses by Albrecht von Halberstadt, dating back to the end of the twelfth century, survives only in few Fragments. In this essay, I will analyse Fragment B, which contains tales from Book XI of the Metamorphoses, in order to assess Albrecht's rewriting techniques, and his simplification of both matter and style. Indeed, Albrecht employs the middle style, while his Latin source was written in a rhetorical and elevated style. Albrecht's Fragments will be compared with the Ovidian source and with the Eneit of Heinrich von Veldeke, highlighting the features shared by the two rewritings of classical texts, which were both commissioned by the Landgrave Hermann of Thuringia

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

Background: 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC. Methods: This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial with a sample size of 159 patients from 20 centers in 3 countries. Patients with stage IV colorectal adenocarcinoma limited to liver metastases are included. Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous metastases, eligible patients are randomized 2:1 to receive either L-BLP25 or placebo. Those allocated to L-BLP25 receive a single dose of 300 mg/m2 cyclophosphamide (CP) 3 days before first L-BLP25 dose, then primary treatment with s.c. L-BLP25 930 mug once weekly for 8 weeks, followed by s.c. L-BLP25 930 mug maintenance doses at 6-week (years 1&2) and 12-week (year 3) intervals unless recurrence occurs. In the control arm, CP is replaced by saline solution and L-BLP25 by placebo. Primary endpoint is the comparison of recurrence-free survival (RFS) time between groups. Secondary endpoints are overall survival (OS) time, safety, tolerability, RFS/OS in MUC-1 positive cancers. Exploratory immune response analyses are planned. The primary endpoint will be assessed in Q3 2016. Follow-up will end Q3 2017. Interim analyses are not planned. Discussion: The design and implementation of such a vaccination study in colorectal cancer is feasible. The study will provide recurrence-free and overall survival rates of groups in an unbiased fashion. Trial Registration EudraCT Number 2011-000218-2

Dissertatio Inavgvralis Medica De Methodo Refrigerante Et Antiphlogistica Per Recentiorvm De Calore Animali Doctrinam Explicata

Erfurt, Univ., Med. Diss., 1790Qvam ... Pro Gradv Doctoris Svmmisqve In Arte Salvtari Honoribvs Ac Privilegiis Legitime Impetrandis Praeside D. Avgvsto Friederich Hecker Facvltatis Medicae Professore Pvblico Ordinario Et Adsessore Extraordinario Pvblice Defendet Fridericvs Erdmann Schroeder Wernigerodanvs In Avditorio Medico Die XX. Septembris MDCCXCAutopsie nach Ex. der ULB Sachsen-AnhaltVorlageform des Erscheinungsvermerks: Erfordiae, Typis Henric. Rvdolphi Nonnii, Academiae Typograph